tiprankstipranks
Advertisement
Advertisement

DSKYF Stock Latest News

DSKYF Upcoming Earnings Report: What to Expect?
Pre-EarningsDSKYF Upcoming Earnings Report: What to Expect?
5d ago
Daiichi Sankyo Advances ADC Pipeline With New Esophageal Cancer Study
PremiumCompany Announcements
Daiichi Sankyo Advances ADC Pipeline With New Esophageal Cancer Study
11d ago
DSKYF
Daiichi Sankyo Terminates Early Cancer Trial DS-9606a: What Investors Should Know
PremiumCompany Announcements
Daiichi Sankyo Terminates Early Cancer Trial DS-9606a: What Investors Should Know
1M ago
DSKYF
Daiichi Sankyo Backs Triple Cholesterol Therapy in New Phase 3 Heart Study
PremiumCompany Announcements
Daiichi Sankyo Backs Triple Cholesterol Therapy in New Phase 3 Heart Study
1M ago
DSKYF
Daiichi Sankyo Advances Triple Cholesterol Combo Pill With Completed Bioequivalence Study
PremiumCompany Announcements
Daiichi Sankyo Advances Triple Cholesterol Combo Pill With Completed Bioequivalence Study
2M ago
DSKYF
Bayer and Daiichi Sankyo Advance New Prostate Cancer Combo in Early-Stage Trial
PremiumCompany AnnouncementsBayer and Daiichi Sankyo Advance New Prostate Cancer Combo in Early-Stage Trial
3M ago
Daiichi Sankyo Reports January Progress on Ongoing Share Buyback Program
Premium
Company Announcements
Daiichi Sankyo Reports January Progress on Ongoing Share Buyback Program
3M ago
Daiichi Sankyo Publishes Q3 FY2025 Consolidated Financial Reference Data
Premium
Company Announcements
Daiichi Sankyo Publishes Q3 FY2025 Consolidated Financial Reference Data
3M ago
Daiichi Sankyo Company (DSKYF) Q3 Earnings Cheat Sheet
PremiumPre-Earnings
Daiichi Sankyo Company (DSKYF) Q3 Earnings Cheat Sheet
3M ago
TROPION-SWISH: New Phase IV Study Targets Side-Effect Risk in AstraZeneca and Daiichi Sankyo’s Dato-DXd
PremiumCompany Announcements
TROPION-SWISH: New Phase IV Study Targets Side-Effect Risk in AstraZeneca and Daiichi Sankyo’s Dato-DXd
3M ago
AZN
Daiichi Sankyo and Merck Advance Novel ADC Combo in Tough-to-Treat Lung Cancer
PremiumCompany Announcements
Daiichi Sankyo and Merck Advance Novel ADC Combo in Tough-to-Treat Lung Cancer
4M ago
DSKYF
Daiichi Sankyo’s Next Lung Cancer Bet: What the New Merck Partnership Study Means for Investors
PremiumCompany Announcements
Daiichi Sankyo’s Next Lung Cancer Bet: What the New Merck Partnership Study Means for Investors
4M ago
DSKYF
Daiichi Sankyo’s ADC Push in Gastroesophageal Cancer: What Substudy 06D Means for Investors
PremiumCompany AnnouncementsDaiichi Sankyo’s ADC Push in Gastroesophageal Cancer: What Substudy 06D Means for Investors
4M ago
DSKYF
TROPION-Lung17: New Phase III Lung Cancer Trial Adds Medium-Term Upside Potential for AstraZeneca and Daiichi Sankyo
Premium
Company Announcements
TROPION-Lung17: New Phase III Lung Cancer Trial Adds Medium-Term Upside Potential for AstraZeneca and Daiichi Sankyo
4M ago
AZN
Daiichi Sankyo’s CLEAR Taiwan Study: A New Chapter in Lipid-Lowering Therapy
Premium
Company Announcements
Daiichi Sankyo’s CLEAR Taiwan Study: A New Chapter in Lipid-Lowering Therapy
5M ago
DSKYF
3 Best Japanese Stocks to Invest In, According to AI Analyst
PremiumMarket News
3 Best Japanese Stocks to Invest In, According to AI Analyst
5M ago
GS
AZN
Daiichi Sankyo Wins Patent Dispute Appeal Against Seagen
PremiumCompany Announcements
Daiichi Sankyo Wins Patent Dispute Appeal Against Seagen
5M ago
DSKYF Upcoming Earnings Report: What to Expect?
PremiumPre-Earnings
DSKYF Upcoming Earnings Report: What to Expect?
6M ago
Daiichi Sankyo’s Latest Clinical Trial: A Potential Game-Changer for Prostate Cancer Treatment
PremiumCompany Announcements
Daiichi Sankyo’s Latest Clinical Trial: A Potential Game-Changer for Prostate Cancer Treatment
6M ago
DSKYF
Daiichi Sankyo’s Promising Pediatric Cancer Study: A Potential Game-Changer
PremiumCompany AnnouncementsDaiichi Sankyo’s Promising Pediatric Cancer Study: A Potential Game-Changer
6M ago
DSKYF
Daiichi Sankyo’s Promising Gastrointestinal Cancer Study: A Market Game-Changer?
Premium
Company Announcements
Daiichi Sankyo’s Promising Gastrointestinal Cancer Study: A Market Game-Changer?
6M ago
DSKYF
Daiichi Sankyo’s Latest Clinical Study: A Potential Game-Changer in Gastrointestinal Cancer Treatment
Premium
Company Announcements
Daiichi Sankyo’s Latest Clinical Study: A Potential Game-Changer in Gastrointestinal Cancer Treatment
6M ago
DSKYF

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >